miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Cutaneous Melanoma Clinical Trial

Official title:

The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01444560
• Other study ID #: microRNA4
• Status: Completed
• Phase: N/A
• First received: September 29, 2011
• Last updated: October 15, 2012
• Start date: December 2008
• Est. completion date: September 2011

Study information

• Verified date: October 2012
• Source: Ruhr University of Bochum
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of miRNA machinery components such as miRNA maturation and transport factors, microprocessor complex and RISC subunits in cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi.

Description:

Patients with cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi were included in the study. Punch biopsies were harvested from the center of the tumors. The miRNA machinery components were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• cutaneous melanoma

• cutaneous melanoma metastases

• benign melanocytic nevi

Exclusion Criteria:

• other forms of malignancy

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cutaneous Melanoma
• Melanoma
• Nevi
• Nevus
• Nevus, Pigmented

Locations

Country	Name	City	State
Germany	Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum	Bochum	NRW

Sponsors (1)

Lead Sponsor	Collaborator
Ruhr University of Bochum

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, Bechara FG. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012 Oct;350(1):119-26. doi: 10. — View Citation